PROTEIN NMB1125 AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS

摘要

The invention relates to the use of a novel vaccine antigen which is used preventively or therapeutically against diseases of bacterial, viral, cancerous or other origin. The technical aim of the invention is to develop formulations that can increase the protective spectrum of existing vaccines and extend same against different pathogens. For said purpose, protein NMB1125 was isolated and identified as a component of Neisseria meningitidis outer membrane preparations, which can induce bactericide activity. In addition, the gene coding for protein NMB1125 was cloned and expressed, said protein being purified, and the immunogenicity thereof in animal biomodels was subsequently evaluated. The high conservation level of the sequencing of homologous genes demonstrated the high value thereof as an antigen that induces a cross immune response when presented in different ways. The resulting formulations are suitable for use in the pharmaceutical industry as vaccine formulations for human use.